Selective Elimination of HIV-1-Infected Macrophages by Targeted Activator of Cell Kill

In the pursuit of an HIV cure, elimination of persistent HIV reservoirs requires strategies that promote immune-mediated or cytopathic clearance of infected cells. While many such approaches are being developed against infected CD4+ T cells, HIV-infected macrophages are comparatively resistant to cell death and to several killing mechanisms being explored for T-cell reservoirs, highlighting the need for strategies that specifically eliminate this reservoir. Targeted Activator of Cell Kill (TACK), developed by Merck Pharmaceuticals, are non-nucleoside reverse transcriptase inhibitor-derived molecules designed to selectively kill HIV-1-infected cells by inducing premature activation of the viral protease. Here, we evaluated the TACK compounds Pyr01 and it?s inactive analog Pyr02, in primary human monocyte-derived macrophages (MDMs). Pyr01 had minimal effects on uninfected MDM viability but potently targeted HIV-1-infected MDMs, with an EC?? of approximately 0.36 ?M. Pyr01 treatment produced a rapid and sustained reduction in extracellular virion-associated HIV-1 RNA and significantly decreased cell-associated viral RNA, whereas Pyr02 exhibited minimal activity. Immunofluorescence microscopy and live-cell imaging further demonstrated a marked loss of HIV-1-infected macrophages following Pyr01 treatment, consistent with selective elimination of infected cells. These findings identify Pyr01 as a specific mediator of HIV-infected macrophage death and establish premature viral protease activation as a strategy for overcoming the intrinsic resistance of macrophage reservoirs to clearance. Targeting this macrophage-specific barrier may complement approaches directed at CD4+ T-cell reservoirs and broaden the cellular reach of HIV cure strategies.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.11.765927
Primary Topic
HIV Research and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Selective Elimination of HIV-1-Infected Macrophages by Targeted Activator of Cell Kill

Mario Stevenson, Anouk A.J. Hamers, Thaissa Isaias Cordeiro, Beatriz M. Lahoz
bioRxiv (Cold Spring Harbor Laboratory)
HIV Research and Treatment
preprint

Selective Elimination of HIV-1-Infected Macrophages by Targeted Activator of Cell Kill

Mario Stevenson, Anouk A.J. Hamers, Thaissa Isaias Cordeiro, Beatriz M. Lahoz
preprint en

Abstract

In the pursuit of an HIV cure, elimination of persistent HIV reservoirs requires strategies that promote immune-mediated or cytopathic clearance of infected cells. While many such approaches are being developed against infected CD4+ T cells, HIV-infected macrophages are comparatively resistant to cell death and to several killing mechanisms being explored for T-cell reservoirs, highlighting the need for strategies that specifically eliminate this reservoir. Targeted Activator of Cell Kill (TACK), developed by Merck Pharmaceuticals, are non-nucleoside reverse transcriptase inhibitor-derived molecules designed to selectively kill HIV-1-infected cells by inducing premature activation of the viral protease. Here, we evaluated the TACK compounds Pyr01 and it?s inactive analog Pyr02, in primary human monocyte-derived macrophages (MDMs). Pyr01 had minimal effects on uninfected MDM viability but potently targeted HIV-1-infected MDMs, with an EC?? of approximately 0.36 ?M. Pyr01 treatment produced a rapid and sustained reduction in extracellular virion-associated HIV-1 RNA and significantly decreased cell-associated viral RNA, whereas Pyr02 exhibited minimal activity. Immunofluorescence microscopy and live-cell imaging further demonstrated a marked loss of HIV-1-infected macrophages following Pyr01 treatment, consistent with selective elimination of infected cells. These findings identify Pyr01 as a specific mediator of HIV-infected macrophage death and establish premature viral protease activation as a strategy for overcoming the intrinsic resistance of macrophage reservoirs to clearance. Targeting this macrophage-specific barrier may complement approaches directed at CD4+ T-cell reservoirs and broaden the cellular reach of HIV cure strategies.

bioRxiv (Cold Spring Harbor Laboratory)
University of Miami (US)
Good health and well-being
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon